Forside  
Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Publiseringsdato
Utgiver(e) Redaktør Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft hos barn, 2017
  • Engelsk tittel -
  • Versjon - 3
  • Status - Publisert
  • IS-nr - 2366
  • ISBN - 978-82-8081-409-8
  • DOI -
  • Revisjonsdato -
  • Neste revisjon -
  • Publikasjonsdato - 10.01.2017
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør - Marit Hellebostad et al
  • Publikasjonstype - Nasjonale retningslinjer
 

1.       Norsk barnekreftregister, Årsrapport 1985–2014. Kreftregisteret 2015.

2        Kaatsch P, Steliarova-Foucher E, Crocetti E, Magnani C, Spix C, Zambon P. Time trends of cancer incidence in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):1961–71.

3        Bosetti C, Bertuccio P, Chatenoud L, Negri E, Levi F, La VC. Childhood cancer mortality in Europe, 1970–2007. Eur J Cancer 2010;46(2):384–94.

4        Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5 – a population based study. Lancet Oncol 2014; 15: 35–47.

5        Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer 2009;45(6):992–1005.

6        Pizzo PA, Poplack DG, red. Principles and practice of pediatric oncology. 5 utg. Philadelphia: Lippincott Williams & Wilkins; 2006.

7        Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2015.PMID: 26580448.

8        Krepischi AC, Capelli LP, Silva AG, de Araújo ÉS, Pearson PL, Heck B, da Costa CM, de Camargo B, Rosenberg C. Large germline copy number variations as predisposing factor in childhood neoplasms. Future Oncol. 2014;10(9):1627–33. doi: 10.2217/fon.14.41. PMID: 25145432

9        Hodgson SV, Maher ER. A practical guide to human cancer genetics. 2 utg. Cambridge: Cambridge University Press; 1999.

10     Offit K. Clinical cancer genetics: risk counselling and management. New York: Wiley-Liss; 1998.

11     Dahl O, Lehne G, Baksaas I, Kvaløy S, Christoffersen T, red. Medikamentell kreftbehandling: cytostatikaboken. 7 utg. Oslo: Farmakologisk institutt, Det medisinske fakultet, Universitetet i Oslo; 2009. Tilgjengelig fra: http://cytostatikaboken.moses.no/index.php

12     Lundar T, Due-Tønnessen BJ, Egge A, Scheie D, Brandal P, Stensvold E, Due-Tønnessen P. Neurosurgical treatment of pediatric low-grade midbrain tumors: a single consecutive institutional series of 15 patients. J Neurosurg Pediatr 2014; 14(6):598–603.

13     Due-Tønnessen BJ, Lundar T, Egge A, Scheie D. Neurosurgical treatment of low-grade cerebellar astrocytoma in children and adolescents: a single consecutive institutional series of 100 patients. J Neurosurg Pediatr 2013;11(3):245–9.

14     Lote K, Hatlevoll R, Bakke SJ, Due-Tønnessen B, Helseth E, Lundar T, et al. Langtids overlevelse etter kirurgi og strålebehandling av hjernesvulster i barnealder. Tidsskr Nor Laegeforen 2000;120(10):1142–5.

15     Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355(15):1572–82.

16     Olsen DR, Bruland OS, Frykholm G, Norderhaug IN. Proton therapy – a systematic review of clinical effectiveness. Radiother Oncol 2007;83(2):123–32.

17     Akuttveileder i pediatri [e-bok]. 3 utg. Tromsø: Norsk barnelegeforening; 2013. Tilgjengelig fra: http://www.helsebiblioteket.no/retningslinjer/akuttveileder-i-pediatri/forside

18     Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14(12):2267–75.

19     Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010;24(2):345–54.

20     Kolmannskog S, Flaegstad T, Helgestad J, Hellebostad M, Zeller B, Glomstein A. Akutt lymfatisk leukemi hos barn i Norge 1992–2000. Tidsskr Nor Laegeforen 2007;127(11):1493–5.

21     Forestier E, Schmiegelow K. The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol 2006;28(8):486–95.

22     Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program 2006: 142–6.

23     Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354(2):166–78.

24     Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004: 118–45.

25     Pieters R, Schrappe M, De LP, Hann I, De RG, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370(9583):240–50.

26     Mann G, Attarbaschi A, Schrappe M, De LP, Peters C, Hann I, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010;116(15):2644–50.

27     Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, Jahnukainen K, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 2012;120(5):978–84.

28     Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials. Leukemia 2005;19(12):2090–100.

29     Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005;128(6):797–804.

30     Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19(8):1355–60.

31     Abildgaard L, Ellebaek E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006;85(5):275–80.

32     Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012;119(8):1821–30.

33     Gustafsson B, Hellebostad M, Ifversen M, Sander B, Hasle H. Acute respiratory failure in 3 children with juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 2011;33(8):e363-e7.

34     Reiter A. Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007: 285–96.

35     Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol 2010;28(19):3115–21.

36     Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia 2013;27(5):1174–7.

37     Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents; progress through effective collaboration, current knowledge and challenges ahead. J of Clin Oncol 2015; 33(27):2963–2974

38     Larsen IK, red. Cancer in Norway 2011: Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2013. Tilgjengelig fra: http://www.kreftregisteret.no/Global/Cancer%20in%20Norway/2011/cin2011_with_special_issue-NORDCAN.pdf

39     Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne lymfomer. Rev utg. Oslo: Helsedirektoratet; 2012. IS-1594. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-maligne-lymfomer/Sider/default.aspx

40     Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, Shankar A, Dorffel W, Wallace WH, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007;110(1):179–85.

41     Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111(1):109–11.

42     Dorffel W, Ruhl U, Luders H, Claviez A, Albrecht M, Bokkerink J, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol 2013;31(12):1562–8.

43     Mauz-Korholz C, Hasenclever D, Dorffel W, Ruschke K, Pelz T, Voigt A, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010;28(23):3680–6.

44     Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25(24):3746–52.

45     Schellong G, Dorffel W, Claviez A, Korholz D, Mann G, Scheel-Walter HG, et al. Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005;23(25):6181–9.

46     Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J of Med 2015;372(4):311–9.

47     Abla O, Egeler RM, Weitzman S. Langerhans cell histiocytosis: Current concepts and treatments. Cancer Treat Rev 2010;36(4):354–9.

48     Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007;166(2):95–109.

49     Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991;80(4):428–35.

50     Ready PD. Leishmaniasis emergence in Europe. Euro Surveill 2010;15(10):19505.

51     Strauss R, Neureiter D, Westenburger B, Wehler M, Kirchner T, Hahn EG. Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients--a postmortem clinicopathologic analysis. Crit Care Med 2004;32(6):1316–21.

52     Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48(2):124–31.

53     Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, red WHO classification of tumours of the central nervous system. 4. utg. Lyon: IARC Press; 2007. World Health Organization classification of tumours.

54     Stokland T, Liu JF, Ironside JW, Ellison DW, Taylor R, Robinson KJ, et al. A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol 2010;12(12):1257–68.

55     Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118(5):1739–49.

56     Stiller C, red. Childhood Cancer in Britain: incidence, survival, mortality. Oxford: Oxford University Press; 2007.

57     Gnekow AK, Packer R, Kortmann RD. Astrocytic tumors, low-grade. I: Walker DV, Perilongo G, Punt JAG, Taylor R, red. Brain and spinal tumors of childhood. London: Arnold; 2004. s. 245–76.

58     Perilongo G. Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma. J Neurooncol 2005;75(3):301–7.

59     Reddy AT, Packer RJ. Chemotherapy for low-grade gliomas. Childs Nerv Syst 1999;15(10):506–13.

60     Due-Tønnessen BJ, Helseth E, Scheie D, Skullerud K, Aamodt G, Lundar T. Long-term outcome after resection of benign cerebellar astrocytomas in children and young adults (0–19 years): report of 110 consecutive cases. Pediatr Neurosurg 2002;37(2):71–80.

61     Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 2013;60(5):776–82.

62     Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012;30(12):1358–63.

63     Lannering B, Sandstrom PE, Holm S, Lundgren J, Pfeifer S, Samuelsson U, et al. Classification, incidence and survival analyses of children with CNS tumours diagnosed in Sweden 1984–2005. Acta Paediatr 2009;98(10):1620–7.

64     Hargrave D. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg 2009;23(4):351–63.

65     Reni M, Gatta G, Mazza E, Vecht C. Ependymoma. Crit Rev Oncol Hematol 2007;63(1):81–9.

66     Zacharoulis S, Moreno L. Ependymoma: an update. J Child Neurol 2009;24(11):1431–8.

67     Lundar T, Due-Tønnessen BJ, Scheie D, Brandal P. Pediatric spinal ependymomas: an unpredictable and puzzling disease. Long-term follow-up of a single consecutive institutional series of ten patients. Childs Nerv Syst. 2014 Dec;30(12):2083–8.

68     Timmermann B, Kortmann RD, Kuhl J, Rutkowski S, Dieckmann K, Meisner C, et al. Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: results of the prospective German brain tumor trials HIT-SKK 87 and 92. Radiother Oncol 2005;77(3):278–85.

69     Conter C, Carrie C, Bernier V, Geoffray A, Pagnier A, Gentet JC, et al. Intracranial ependymomas in children: society of pediatric oncology experience with postoperative hyperfractionated local radiotherapy. Int J Radiat Oncol Biol Phys 2009;74(5):1536–42.

70     Tamburrini G, D’Ercole M, Pettorini BL, Caldarelli M, Massimi L, Di RC. Survival following treatment for intracranial ependymoma: a review. Childs Nerv Syst 2009;25(10):1303–12.

71     Rutkowski S, von BA, von HK, Hartmann W, Shalaby T, Deinlein F, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT’91. Clin Cancer Res 2007;13(9):2651–7.

72     Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005;352(10):978–86.

73     Rutkowski S. Current treatment approaches to early childhood medulloblastoma. Expert Rev Neurother 2006;6(8):1211–21.

74     Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen JC, Finlay JL, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol 1995;13(7):1687–96.

75     Timmermann B, Kortmann RD, Kuhl J, Rutkowski S, Meisner C, Pietsch T, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol 2006;24(10):1554–60.

76     Massimino M, Gandola L, Spreafico F, Luksch R, Collini P, Giangaspero F, et al. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy. Int J Radiat Oncol Biol Phys 2006;64(4):1031–7.

77     Muller HL. Childhood craniopharyngioma: current controversies on management in diagnostics, treatment and follow-up. Expert Rev Neurother 2010;10(4):515–24.

78     Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 2007;106(1 Suppl):3–12.

79     Kortmann RD. Different approaches in radiation therapy of craniopharyngioma. Front Endocrinol (Lausanne) 2011;2:100.

80     Bartels U, Laperriere N, Bouffet E, Drake J. Intracystic therapies for cystic craniopharyngioma in childhood. Front Endocrinol (Lausanne) 2012;3:39.

81     Due-Tønnessen B, Helseth E, Skullerud K, Lundar T. Choroid plexus tumors in children and young adults: report of 16 consecutive cases. Childs Nerv Syst 2001;17(4–5):252–6.

82     Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, et al. Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol. 2009;95(3):383–92

83     Berrak SG, Liu DD, Wrede B, Wolff JE. Which therapy works better in choroid plexus carcinomas? J Neurooncol 2011;103(1):155–62.

84     Childhood cancer in the Nordic countries. Linköping: Nordic society of Pediatric Haematology and Oncology; 2008.

85     Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21(10):2011–8.

86    Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for utredning, behandling og oppfølging av sarkom. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-sarkom

87     Paulussen M, Kovar H, Jürgens H. Ewing sarcoma and peripheral primitive neuroectodermal tumour. I: Voûte PA, Barrett A, Stevens MCG, Carson HN, red. Cancer in children: clinical management. 5 utg. Oxford: Oxford University Press; 2005. s. 301–20.

88     Bisogno G, Bergeron C. Soft tissue sarcoma. I: Voûte PA, Barrett A, Stevens MCG, Carson HN, red. Cancer in children: clinical management. 5 utg. Oxford: Oxford University Press; 2005. s. 255–79.

89     ISG/SSG III Treatment protocol for nonmetastatic Ewing’s family tumors. Bologna og Lund: Italian Sarcoma Group, Scandinavian Sarcoma Group og Oncologic Center; 1999. Tilgjengelig fra: http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/ISGSSG3-1999.pdf

90     ISG/SSG IV Treatment protocol for high risk Ewing’s family tumors. Bologna og Lund: Italian Sarcoma Group, Scandinavian Sarcoma Group og Oncologic Center; 1999. Tilgjengelig fra: http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/ISGSSGIV-1999.pdf

91     RMS 2005: a protocol for non metastatic rhabdomyosarcoma. Version 1.3 International. [s.l.]: European paediatric soft tissue sarcoma study group; 2012. Tilgjengelig fra: https://www.skion.nl/workspace/uploads/Protocol-EpSSG-RMS-2005-1-3-May-2012_1.pdf

92     NRSTS 2005: a protocol for localized non rhabdomyosarcoma soft tissue sarcomas. Verson 1.1. [s.l.]: European paediatric soft tissue sarcoma study group; 2009. Tilgjengelig fra: https://www.skion.nl/workspace/uploads/EpSSG-NRSTS-version-1-1.pdf

93     EURAMOS I [Upublisert randomisert kontrollert studie]. [s.l.]: European and American Osteosarcoma Study Group. Tilgjengelig fra: http://www.ctu.mrc.ac.uk/euramos/euramos_i_trial.asp

94     Helsedirektoratet. Nasjonal faglig retningslinje for palliativ behannling til barn og unge uavhengig av diagnose. Tilgjengelig fra: https://helsedirektoratet.no/Retningslinjer/Palliativ%20behandling%20barn%20og%20unge.pdf

95     Pritchard-Jones K, Pritchard J. Success of clinical trials in childhood Wilms’ tumour around the world. Lancet 2004;364(9444):1468–70.

96     Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet 1998;79(4):268–73.

97     Kaste SC, Dome JS, Babyn PS, Graf NM, Grundy P, Godzinski J, et al. Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatr Radiol 2008;38(1):2–17.

98     Wright KD, Green DM, Daw NC. Late effects of treatment for wilms tumor. Pediatr Hematol Oncol 2009;26(6):407–13.

99     Spreafico F, Pritchard JK, Malogolowkin MH, Bergeron C, Hale J, de KJ, et al. Treatment of relapsed Wilms tumors: lessons learned. Expert Rev Anticancer Ther 2009;9(12):1807–15.

100   Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27(2):298–303.

101   Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27(2):289–97.

102   Pinto NR, Applebaum MA, Volchenboum, Matthay KK, London W, Ambros PF et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 2015;33(27):3008–17

103   Yu AL, Gilman MF, Ozkaynak WB, London S, Kreissman H, Chen KK, et al. A Phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children’s Oncology Group (COG) Study ANBL0032. J Clin Oncol 2009;29(suppl 15s):abstr 10067z.

104   Gaze M N, Chang Y-C, Flux G D, Mairs R J, Saran F H, Meller S T. «Feasibility of Dosimetry-Based High-Dose 131I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastome.» Cancer Biotherapy & Radiopharmaceuticals 2005; 20; 2; 195–199

105   Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 2005;23(6):1245–52.

106   Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009;361(17):1662–70.

107   Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, et al. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. Eur J Cancer 2004;40(3):411–21.

108   Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000;18(22):3819–28.

109   Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, et al., for the International Childhood Liver Tumours Strategy Group (SIOPEL)* Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013 Aug;14(9):834–42).

110   Gobel U, Calaminus G, Engert J, Kaatsch P, Gadner H, Bokkerink JP, et al. Teratomas in infancy and childhood. Med Pediatr Oncol 1998;31(1):8–15.

111   Gobel U, Schneider DT, Calaminus G, Haas RJ, Schmidt P, Harms D. Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. Ann Oncol 2000;11(3):263–71.

112   Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, et al. The United Kingdom Children’s Cancer Study Group’s second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000;18(22):3809–18.

113. Nordiske retningslinjer for retinoblastom 2016 [Available from: http://www.nopho.org/member_pages/member_area/workinggroups/retinoblastom/Nordiske%20retningslinjer%20for%20utreding%20og%20behandling%20av%20Retinoblastom_v2_2016-05.pdf.

114   Gregersen PA, Urbak SF, Funding M, Overgaard J, Jensen UB, Alsner J. Danish retinoblastoma patients 1943–2013 – genetic testing and clinical implications. Acta Oncol. 2016;55(4):412–7.

115   Yousef YA, Al-Hussaini M, Mehyar M, Sultan I, Jaradat I, AlRawashdeh K, et al. PREDICTIVE VALUE OF TNM CLASSIFICATION, INTERNATIONAL CLASSIFICATION, AND REESE-ELLSWORTH STAGING OF RETINOBLASTOMA FOR THE LIKELIHOOD OF HIGH-RISK PATHOLOGIC FEATURES. Retina. 2015;35(9):1883–9.

116   A.M. Intraocular retinoblastoma: the case for a new group classification. Ophthalamic Oncology, Ophthalmology Clinics of North America. 2005;18:41–53.

117   Rosengren B, Monge OR, Flage T. Proposal of a new pretreatment clinical TNM-classification of retinoblastoma. Acta Oncol. 1989;28(4):547–8.

118   Kim JW, Abramson DH, Dunkel IJ. Current management strategies for intraocular retinoblastoma. Drugs. 2007;67(15):2173–85.

119   Kohno S, Kitajima S, Sasaki N, Takahashi C. Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies. World J Stem Cells. 2016;8(4):170–84.

120   Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323(6089):643–6.

121   Knudson A G Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Nat Acad Sci. 1971;68(4):820–823.

122   Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, et al. Retinoblastoma. Lancet. 2012;379(9824):1436–46.

123   Sandven-Thrane S. [Leucocoria is retinoblastoma until the opposite is proven]. Tidsskr Nor Laegeforen. 2012;132(18):2042.

124   Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol. 2004;138(3):329–37.

125   Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol. 2001;119(9):1269–72.

126   Retinoblastom. State of the art [Available from: http://www.socialstyrelsen.se/ovanligadiagnoser/retinoblastom.

127   Abramson DH, Greenfield DS, Ellsworth RM. Bilateral retinoblastoma. Correlations between age at diagnosis and time course for new intraocular tumors. Ophthalmic Paediatr Genet. 1992;13(1):1–7.

128   Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272–9.

129   Kleinerman RA, Yu CL, Little MP, Li Y, Abramson D, Seddon J, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol. 2012;30(9):950–7.

130   Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN, et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32(29):3284–90.

131   Turaka K, Shields CL, Meadows AT, Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer. 2012;59(1):121–5.

132. Klingenberg C, Möller T, Nilsen CV, Døllner H, Rajka T, red. Generell veileder i pediatri [e-bok]. 2 utg. Tromsø: Norsk barnelegeforening; 2012. Tilgjengelig fra: http://www.helsebiblioteket.no/retningslinjer/pediatri/forside

133   Gibson BE, Todd A, Roberts I, Pamphilon D, Rodeck C, Bolton-Maggs P, et al. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124(4):433–53.

134   Rutter M, Bishop D, Pine D, Scott S, Stevenson J, Taylor E, et al., red. Rutter’s child and adolescent psychiatry. 5 utg. Oxford: Blackwell Publ.; 2008.

135   Reinfjell T, Diseth T, Vikan A. Barn og kreft: Barns tilpasning til og forståelse av alvorlig sykdom. Tidsskrift for Norsk Psykologforening 2007;44(6):724–34.

136   Van Dongen-Melman JE, Pruyn JF, De GA, Koot HM, Hahlen K, Verhulst FC. Late psychosocial consequences for parents of children who survived cancer. J Pediatr Psychol 1995;20(5):567–86.

137   Foreldrekontakttjenesten [nettside]. Oslo: Barnekreftforeningen [oppdatert 2013; lest 8. aug. 2013]. Tilgjengelig fra: http://www.barnekreftforeningen.no/for-medlemmer/foreldre-m/

138   Immunisation of the immunocompromised child: best practise statement. London: Royal College of Paediatrics in Child Health; 2002. Tilgjengelig fra: http://www.rcpch.ac.uk/sites/default/files/asset_library/Publications/I/Immunocomp.pdf

139   Abzug MJ. Vaccination in the immunocompromised child: a probe of immune reconstitution. Pediatr Infect Dis J 2009;28(3):233–6.

140   Ek T, Nilsson A. Vaccinationer vid barncancer: ett svenskt vaccinationsprogram för barn som behandlats med cytostatika för maligna sjukdomar. [s.l.]: Svenska Barnläkarföreningens sektion för Pediatrisk Hematologi och Onkologi; 2013. Tilgjengelig fra: http://www.blf.net/onko/page16/files/Vaccinationsprogram%20v%201.pdf

141   Esposito S, Cecinati V, Brescia L, Principi N. Vaccinations in children with cancer. Vaccine 2010;28(19):3278–84.

142   Nøkleby H. Vaksinasjon av pasienter med nedsatt immunforsvar. Tidsskr Nor Laegeforen 2002;122(28):2711–2.

143   Anbefalinger for bruk av pneumokokkvaksine utenfor barnevaksinasjonsprogrammet i Norge, rapport 2015: 7, Folkehelseinstituttet (http://www.fhi.no/artikler/?id=116885)

144   Vaccination of immunocompromised persons. The Australian Immunisation handbook, Australian government, Department of Health. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part3~handbook10-3-3#3-3-3

145   Rubin et al., 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis. (2014), 58(3)

146   Reilly A, Kersun LS, McDonald K et al. The efficacy of influenza vaccination in a pediatric oncology population. J Pediatr Hematol Oncol 2010; 32(5):e177–81.

147   Caniza MA, Hunger SP, Schrauder A, et al. The controversy of varicella vaccination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58(1): 12–6.

148   Schrauder A, Henke-Gendo C, Seidemann K, et al. Varicella vaccination in a child with acute lymphoblastic leukemia. Lancet 2007; 369(9568): 1232.

149   Smedegaard LM, Poulsen A, Kristensen IA, et al. Varicella vaccination of children with leukemia without interruption of maintenance therapy: A Danish experience. Pediatr Infect Dis J. 2016; 35(11):e348–352.

150   Ljungman et al., Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplantation (2009), 44, 521‐526

151   Meningokokksykdom i Norge og anbefalinger for bruk av meningokokkvaksiner, rapport 2014: 5, Folkehelseinstituttet (http://www.fhi.no/artikler/?id=113102)

152   Fosså SD, Loge JH, Dahl AA, red. Kreftoverlevere: ny kunnskap og nye muligheter i et langtidsperspektiv. Oslo: Gyldendal akademisk; 2009.

153   Wallace WH, Blacklay A, Eiser C, Davies H, Hawkins M, Levitt GA, et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ 2001;323(7307):271–4.

154   Wallace H, Green DM, red. Late effects of childhood cancer. London: Arnold; 2004.

155   Dickerman JD. The late effects of childhood cancer therapy. Pediatrics 2007;119(3):554–68.

156   Syse A. Does cancer affect marriage rates? J Cancer Surviv. 2008; 2(3):205–14.

157   Gunnes MW, Lie RT, Bjørge T, et al. Reproduction and marriage among male survivors of cancer in childhood, adolescence and adulthood: a national cohort study. Br J of Cancer. 2016;114(3):348–56.

158   Hamre H, Zeller B, Kanellopoulos A et al. High Prevalence of Chronic Fatigue in Adult Long-Term Survivors of Acute Lymphoblastic Leukemia and Lymphoma During Childhood and Adolescence. Journal of Adolescent and Young Adult Oncology 2013; 2: 2–9

159   Oppfølging av kreftoverlevere med særlig fokus på seneffekter: innstilling fra en arbeidsgruppe nedsatt av Helsedirektoratet. Oslo: Arbeidsgruppen; 2010. Tilgjengelig fra: https://www.nsf.no/ikbViewer/Content/737510/Rapport_fra_arbeids_340659

160   Levisohn L, Cronin-Golomb A, Schmahmann JD. Neuropsychological consequences of cerebellar tumour resection in children: cerebellar cognitive affective syndrome in a paediatric population. Brain 2000;123 (Pt 5):1041–50.

161   Mulhern RK. Cognitive sequelae. Brain Injury 2003;17(Suppl 1):5.

162   Mulhern RK, Butler RW. Neurocognitive sequelae of childhood cancers and their treatment. Pediatr Radiol 2004;7(1):1–14.

163   Aarsen FK, Van Dongen HR, Paquier PF, Van MM, Catsman-Berrevoets CE. Long-term sequelae in children after cerebellar astrocytoma surgery. Neurology 2004;62(8):1311–6.

164   Rønning C, Sundet K, Due-Tønnessen B, Lundar T, Helseth E. Persistent cognitive dysfunction secondary to cerebellar injury in patients treated for posterior fossa tumors in childhood. Pediatr Neurosurg 2005;41(1):15–21.

165   Hagberg-van’t Hooft I. Cognitive rehabilitation in children with acquired brain injuries [doktorgrad]. Stockholm: Karolinska institutet, Department of Women’s and Children’s Health; 2005. Tilgjengelig fra: http://publications.ki.se/xmlui/bitstream/handle/10616/39503/thesis.pdf?sequence=1

166   Beslutningsprosesser for begrensning av livsforlengende behandling hos alvorlige syke og døende. Oslo: Helsedirektoratet; 2013. IS-2091. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/beslutningsprosesser-ved-begrensning-av-livsforlengende-behandling

167   Retningslinjer for smertelindring. Oslo: Den norske legeforening; 2009. Tilgjengelig fra: http://legeforeningen.no/pagefiles/42355/retningslinjer%20smertebehandling%20dnlf.pdf

168   Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartemenetet; 2006. Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6. Tilgjengelig fra: http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf